Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Sjögren’s syndrome (SS) is an autoimmune disease with heterogeneous clinical pictures, which extend from benign local exocrinopathy that affects primarily the salivary and lachrymal glands to systemic disorder, and in approximately 5% of patients evolves to B-cell malignancies. Furthermore, SS can be expressed as an isolated clinical entity or coexpressed with virtually every other systemic autoimmune rheumatic disorder. Most of these features are present at diagnosis and do not change during follow-up treatment, suggesting that SS is a slowly progressive disease. Studies have identified clinical, laboratory, and histopathologic features, which predict the patients that are at high risk to develop lymphoproliferative disorder. Thus purpura, cryoglobulinemia, leukopenia, C3 and C4 hypocomplementemia, as well as persistent salivary gland enlargement, have been recognized as adverse prognostic indicators. Most importantly, in the majority of SS patients who are at high risk of lymphoma development, palpable purpura, cryoglobulinemia, and C4 hypocomplementemia are present at the time of diagnosis and thus can be used as predicting factors of adverse outcome. All these features along with the fact that the histopathologic lesions in minor salivary glands (MSGs) are easily accessible render SS as an ideal model for the study of autoimmunity and associated malignancy.
The extensive study of MSG autoimmune lesions revealed that, in accordance with the clinical picture of the disease, the severity and the composition of the histopathologic lesions vary among SS patients and do not significantly change over time. In fact, T cells predominate in mild lesions and B cells in severe, whereas macrophages increase with lesion severity and high incidence has been linked to lymphoma development. Most importantly, the severity and the composition of inflammatory lesions is fully blown at diagnosis and does not significantly change thereafter, with the exception of development of lymphoma in predisposed patients, suggesting that distinct pathogenetic pathways and immune responses operate in SS patients with variable degree of infiltration. Furthermore, the association between the intense salivary gland inflammation and the occurrence of extraglandular systemic manifestations such as Raynaud phenomenon, vasculitis, lymph node/spleen enlargement, and leukopenia, as well as of various histopathological parameters such as formation of ectopic germinal centers, infiltration by certain types of immune cells, and production of cytokines (eg, B-cell activating factor [BAFF], interleukin [IL]18, etc.) with lymphoma development, suggest that the local immune responses in SS are linked to the systemic manifestations of the disorder.
The mechanisms mediating the development and perpetuation of lymphocytic infiltrates, their severity, and the predominance of certain types of immune responses (T- or B-cell driven), as well as the way these could affect the outcome of the disease, have not been fully understood. Emerging data during the past two decades indicate that epithelial cells, which are the major targets of autoimmune responses, are not innocent bystanders but active, key regulators of SS autoimmune responses. Herein we summarize the factors that have been implicated in epithelial cell dysfunction, as well as the findings supporting the significant role of glandular epithelium in the development and regulation of autoimmune responses.
Historically, glandular epithelia in SS were considered to be innocent bystanders experiencing the injurious effects of chronic inflammation and its byproducts, such as function-modulating cytokines and cytotoxic and apoptotic signals that lead to epithelial dysfunction and/or destruction with ultimate result the salivary gland hypofunction. Nevertheless, the severity of salivary gland dysfunction in SS does not necessarily correlate with the degree of lymphocytic infiltration and epithelial loss and destruction, suggesting that the SS secretory functional impairment is not completely dependent on inflammatory processes. On the contrary, oral dryness in SS seems to be a complex phenomenon possibly owing to the reduction and/or inhibition of water transport machinery, as well as an altered quality of the saliva produced by epithelia. Autoimmune responses seem to affect both epithelial secretory function by modulating the underlying pathways and epithelial survival by promoting apoptotic cell death.
The secretion process in salivary glands is controlled by sympathetic and parasympathetic nerve fibers, whereas the differential stimulation of epithelial cholinergic and adrenergic receptors determines the quantity and quality of secreted saliva. Thus acetylcholine stimulation of cholinergic receptors results in saliva rich in water and electrolytes, but low in proteins and glycoproteins, whereas adrenergic stimulation results in exocytosis of protein and glycoproteins with a low water and electrolyte content. Hypothesizing that lymphocytic infiltration could affect glandular innervation, initial observations suggested that vasoactive intestinal peptide–containing nerve fibers are reduced in areas of strong inflammation at the MSG lesions of SS patients; however, later studies showed that innervation and consequent nerve stimulation are not altered in SS patients. Data from mouse models suggested that cytokine-mediated reduced release of neurotransmitters may participate in the salivary hypofunction of SS. Furthermore, the development of autoimmune responses against the muscarinic type 3 acetylcholine receptor (M3R) has been implicated in reduced salivary function of SS patients. M3R plays a critical role in the parasympathetic control of salivation. Autoantibodies against M3R have been described in SS patients and have been shown to reduce fluid secretion by acinar cells via intracellular trafficking of the water transport protein aquaporin-5 (AQP5) in epithelial cells, whereas cellular immune responses against M3R have been associated to epithelial cell destruction; hence immune responses are directly linked with epithelial cell dysfunction in affected salivary glands. AQP5-disturbed expression may also participate in the secretory dysfunction of epithelial cells in SS; even though reports are controversial. Altered distribution of AQP5 in the acini of salivary glands of SS patients has been described. Instead of normal apical membrane distribution, AQP5 was found to localize in the basal membranes of acini in the inflamed MSG tissues of SS patients, whereas tumor necrosis factor (TNF) α, which is abundant in MSG lesions of SS patients, has been implicated in the altered AQP5 expression.
Secretion abnormalities in SS patients do not only involve the quantity of fluid secretion, but also the quality of saliva and particularly mucin production. Mucins are complex O-linked glycoproteins with high content of anionic oligosaccharides acting as hydrophilic polymers that bind water on the epithelial surface and thereby preserve mucosa humidity. Altered expression and trafficking of mucins have been associated with SS. Increased levels, as well as accumulation of mucin 1 (MUC1) in acini cytoplasm, have been described in the MSGs of SS patients and have been linked to proinflammatory cytokine expression. Similar to MUC1, MUC7 was found to accumulate in the cytoplasm of acini in SS patients, and along with MUC5B, was also released via exocytosis in the extracellular matrix. Furthermore, mucins (MUC5B) seem to be hypoglycosylated in SS. In particular, MUC5B hyposulfation has been associated with reduced Gal3-O-sulfotransferase activity, which in turn has been inversely correlated with lymphocyte infiltration and glandular levels of proinflammatory cytokines, suggesting that inflammation might inhibit its activity in SS.
Become a Clinical Tree membership for Full access and enjoy Unlimited articles
If you are a member. Log in here